160 related articles for article (PubMed ID: 34483685)
1. Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B.
Liao G; Ding X; Xia M; Wu Y; Chen H; Fan R; Zhang X; Cai S; Peng J
Int J Gen Med; 2021; 14():4967-4976. PubMed ID: 34483685
[TBL] [Abstract][Full Text] [Related]
2. Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B.
Wang FD; Zhou J; Li LQ; Wang ML; Tao YC; Wang YH; Zhang DM; Chen EQ
Front Microbiol; 2022; 13():901233. PubMed ID: 35814664
[TBL] [Abstract][Full Text] [Related]
3. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
4. Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
BMC Gastroenterol; 2023 Jun; 23(1):224. PubMed ID: 37386460
[TBL] [Abstract][Full Text] [Related]
5. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
6. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
[TBL] [Abstract][Full Text] [Related]
7. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
[TBL] [Abstract][Full Text] [Related]
8. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
Tsai YN; Wu JL; Tseng CH; Chen TH; Wu YL; Chen CC; Fang YJ; Yang TH; Nguyen MH; Lin JT; Hsu YC
Clin Mol Hepatol; 2024 Jan; 30(1):98-108. PubMed ID: 38092551
[TBL] [Abstract][Full Text] [Related]
10. Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.
Hwang SY; Yoo SH; Chang HY; Kim S; Lee JI; Lee KS; Cho YY; Joon KH; Lee HW
J Viral Hepat; 2023 Jan; 30(1):39-45. PubMed ID: 36321949
[TBL] [Abstract][Full Text] [Related]
11. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
12. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
13. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Hsu YC; Nguyen MH; Mo LR; Wu MS; Yang TH; Chen CC; Tseng CH; Tai CM; Wu CY; Lin JT; Tanaka Y; Chang CY
Aliment Pharmacol Ther; 2019 Jan; 49(1):107-115. PubMed ID: 30450681
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
[TBL] [Abstract][Full Text] [Related]
15. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
16. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
Liu Y; Jia M; Wu S; Jiang W; Feng Y
Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
[TBL] [Abstract][Full Text] [Related]
17. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
18. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.
Caviglia GP; Abate ML; Noviello D; Olivero A; Rosso C; Troshina G; Ciancio A; Rizzetto M; Saracco GM; Smedile A
Hepatol Res; 2017 Jul; 47(8):747-754. PubMed ID: 27577976
[TBL] [Abstract][Full Text] [Related]
20. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review.
Jaroenlapnopparat A; Chayanupatkul M; Tangkijvanich P
J Gastroenterol Hepatol; 2021 Sep; 36(9):2349-2362. PubMed ID: 33811375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
